Zacks Investment Research upgraded shares of Enzymotec Ltd. (NASDAQ:ENZY) from a sell rating to a hold rating in a report issued on Tuesday.
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Several other equities analysts also recently issued reports on ENZY. Jefferies Group restated a hold rating and set a $7.00 price objective (down previously from $8.00) on shares of Enzymotec in a report on Monday, November 28th. Wells Fargo & Company downgraded shares of Enzymotec from an outperform rating to a market perform rating in a report on Thursday, November 17th.
Shares of Enzymotec (NASDAQ:ENZY) traded down 0.64% on Tuesday, hitting $7.80. 15,312 shares of the company traded hands. The firm has a market capitalization of $177.52 million, a P/E ratio of 72.90 and a beta of 1.19. The firm’s 50-day moving average is $6.68 and its 200 day moving average is $7.30. Enzymotec has a 1-year low of $5.20 and a 1-year high of $10.00.
Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings data on Wednesday, November 16th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.04. Enzymotec had a net margin of 4.82% and a return on equity of 1.95%. The company had revenue of $11.40 million for the quarter, compared to analyst estimates of $13.29 million. During the same quarter last year, the company earned $0.08 EPS. The business’s revenue was down 8.1% compared to the same quarter last year. On average, analysts anticipate that Enzymotec will post $0.18 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the company. Van ECK Associates Corp increased its position in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock valued at $106,000 after buying an additional 706 shares during the period. TFS Capital LLC acquired a new position in shares of Enzymotec during the second quarter valued at $153,000. State of New Jersey Common Pension Fund D increased its position in shares of Enzymotec by 13.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 24,997 shares of the company’s stock valued at $175,000 after buying an additional 2,976 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Enzymotec by 12.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 21,313 shares of the company’s stock valued at $178,000 after buying an additional 2,298 shares during the period. Finally, Icon Advisers Inc. Co. increased its position in shares of Enzymotec by 87.0% in the third quarter. Icon Advisers Inc. Co. now owns 31,417 shares of the company’s stock valued at $220,000 after buying an additional 14,617 shares during the period. Institutional investors own 35.93% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Get a free copy of the Zacks research report on Enzymotec (ENZY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com